share_log

Antibe Therapeutics Inc. to Post FY2023 Earnings of ($0.39) Per Share, Echelon Wealth Partners Forecasts (TSE:ATE)

Antibe Therapeutics Inc. to Post FY2023 Earnings of ($0.39) Per Share, Echelon Wealth Partners Forecasts (TSE:ATE)

安提貝治療公司將公佈2023財年每股收益(0.39美元)，Echelon Wealth Partners Forecast(TSE：ATE)
Defense World ·  2022/08/19 04:01

Antibe Therapeutics Inc. (TSE:ATE – Get Rating) – Echelon Wealth Partners decreased their FY2023 earnings per share (EPS) estimates for shares of Antibe Therapeutics in a research note issued to investors on Monday, August 15th. Echelon Wealth Partners analyst S. Quenneville now forecasts that the company will earn ($0.39) per share for the year, down from their prior forecast of ($0.38). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.65) per share.

安提貝治療公司(多倫多證券交易所股票代碼：ATE-GET評級)--Echelon Wealth Partners在8月15日星期一發布給投資者的一份研究報告中下調了對安提貝治療公司股票2023財年每股收益(EPS)的預期。Elhelon Wealth Partners分析師S.Quenneville現在預測，該公司今年的每股收益為0.39美元，低於此前預測的0.38美元。對安提貝治療公司目前全年收益的普遍估計為每股0.65美元。

Get
到達
Antibe Therapeutics
安提貝治療公司
alerts:
警報：

Separately, Brookline Capital Management restated a "buy" rating on shares of Antibe Therapeutics in a research note on Monday.

另外，Brookline Capital Management在週一的一份研究報告中重申了對安替比治療公司股票的“買入”評級。

Antibe Therapeutics Stock Performance

安提貝治療公司股票表現

TSE ATE opened at C$0.66 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 13.07 and a quick ratio of 11.92. The business has a 50 day moving average price of C$0.62 and a 200 day moving average price of C$0.68. The company has a market capitalization of C$34.39 million and a P/E ratio of -1.23. Antibe Therapeutics has a 1-year low of C$0.56 and a 1-year high of C$1.30.
週四，Tse ATE開盤報0.66加元。該公司的債務權益比為0.29，流動比率為13.07，速動比率為11.92。該業務的50日移動均線價格為0.62加元，200日移動均線價格為0.68加元。該公司市值為3439萬加元，市盈率為-1.23。安提貝治療公司的一年低點為0.56加元，一年高位為1.30加元。

Antibe Therapeutics Company Profile

安提貝治療公司簡介

(Get Rating)

(獲取評級)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

安提貝治療公司是一家生物技術公司，致力於在加拿大、歐洲、美國和國際上開發疼痛、炎症和再生醫學領域的新型療法和醫療設備。該公司的藥物旨在防止非類固醇抗炎藥造成的胃腸道損傷和出血。

Featured Stories

專題報道

  • If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
  • Is Sanofi A Buy, Despite Recent Stumbles?
  • Institutional Support For TJX Companies May Cap Gains
  • Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
  • BJ's Wholesale Club Pops, Will Costco Be Next?
  • 如果你討厭超速攝像頭，那麼你會喜歡Verra Mobility Stock
  • 儘管賽諾菲最近跌跌撞撞，但它是買入的嗎？
  • 對TJX公司的機構支持可能限制漲幅
  • 星巴克股票，品牌忠誠度足以成為購買理由嗎
  • BJ‘s批發俱樂部流行音樂，Costco會是下一個嗎？

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《安提貝治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對安替比治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論